The objective of this study is to evaluate the efficacy and safety of ustekinumab, an interleukin (IL)-12/23 inhibitor, in patients with GCA~Hypothesis IL-12/23 pathway blockade may maintain disease remission in patients with GCA~Specific Aims~To evaluate the safety and tolerability of ustekinumab administration in 20 patients with GCA~To evaluate the efficacy of ustekinumab for remission maintenance and glucocorticoid sparing in 20 patients with GCA
The purpose of this study is to determine whether ustekinumab is effective in the treatment of Giant Cell Arteritis (GCA)